Raymond James Maintains Outperform on bluebird bio, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Dane Leone has maintained an 'Outperform' rating on bluebird bio (NASDAQ:BLUE) and raised the price target from $10 to $13.

November 08, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has maintained an 'Outperform' rating on bluebird bio and raised the price target from $10 to $13.
The 'Outperform' rating maintained by Raymond James indicates a positive outlook for bluebird bio. The increase in the price target from $10 to $13 suggests that the analyst believes the stock has potential for growth in the short term. This could lead to an increase in investor confidence and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100